<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="363124">
  <stage>Registered</stage>
  <submitdate>9/10/2012</submitdate>
  <approvaldate>10/10/2012</approvaldate>
  <actrnumber>ACTRN12612001084875</actrnumber>
  <trial_identification>
    <studytitle>The ProVIDe Study. The effect of higher intravenous protein intake for extremely low birthweight babies in the first week after birth on survival free from neurodevelopmental disability at 2 years' corrected age.</studytitle>
    <scientifictitle>For extremely low birthweight babies, does higher intravenous protein intake in the first 5 days after birth improve survival free from neurodevelopmental disability at 2 years' corrected age.</scientifictitle>
    <utrn>U1111-1135-5325</utrn>
    <trialacronym>PROVIDE: The impact of protein IVN on development</trialacronym>
    <secondaryid>NIL</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Extremely preterm birth</healthcondition>
    <healthcondition>Faltering growth / postnatal growth restriction</healthcondition>
    <healthcondition>Neurodevelopmental outcome following preterm birth</healthcondition>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Other diet and nutrition disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Complications of newborn</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>All babies will receive intravenous nutrition according to NICU practices. In addition, babies will be randomised to the intervention or placebo control:

Intervention group: Babies will receive 8.5% intravenous amino acid solution at 0.5 mL/hr via the umbilical arterial catheter (UAC), providing an additional 1 to 2 g/Kg.d protein for 5 days. If the UAC is required for longer than 5 days, the solution will be changed to 0.45% saline.</interventions>
    <comparator>The UAC solution will be 0.45% saline at 0.5 mL/hr maintained for 5 days.</comparator>
    <control>Placebo</control>
    <interventioncode>Prevention</interventioncode>
    <interventioncode>Treatment: Other</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Survival free from neurodevelopmental disability at 2 years corrected age, defined as cerebral palsy, blindness, deafness, developmental delay (defined as a standardised score more than 1 SD below the mean (&lt;-1 SD) on the Bayley Scales of Infant Development Edition 3 [BSID-III] scores), Gross Motor Function Classification System score (Doyle LW: Changing availability of neonatal intensive care for extremely low birthweight infants in Victoria over two decades. Med J Aust 2004, 181(3):136-139).</outcome>
      <timepoint>2 years corrected age</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Body composition (the amount and ratio of lean body mass to fat mass) measured by air displacement plethysmography</outcome>
      <timepoint> 36 weeks corrected gestational age</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Growth velocities for weight, length and head circumference, according to UK WHO growth standards.</outcome>
      <timepoint>Birth to 36 weeks corrected gestational age. </timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Crown heel length, weight and head circumference and body mass index Z-score change according to UK WHO growth standards.</outcome>
      <timepoint>Birth to 36 weeks corrected gestational age. </timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Babies &lt;1,000 g at birth and admitted to NICU with a UAC placed.</inclusivecriteria>
    <inclusiveminage>0</inclusiveminage>
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>24</inclusivemaxage>
    <inclusivemaxagetype>Hours</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Birth weight greater than or equal to 1000 g; admission to NICU &gt;24 hours after birth; multiple birth &gt;2 children; congenital disorder affecting growth; inborn error of metabolism; in danger of imminent death.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Within 24 hours of birth babies will be randomly allocated to treatment and control groups by central randomisation. 

Allocation to intervention or control will be concealed. Allocation to the study will not be concealed.</concealment>
    <sequence>Randomisation Via a web-based interface managed by an independent database controller (IDC). Randomisation will be stratified for recruitment centre, sex and for appropriate-for-gestational-age / small-for-gestational-age status.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>nil</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1>True</masking1>
    <masking2>True</masking2>
    <masking3>True</masking3>
    <masking4>True</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate>23/04/2014</anticipatedstartdate>
    <actualstartdate>29/04/2014</actualstartdate>
    <anticipatedenddate>30/06/2017</anticipatedenddate>
    <actualenddate />
    <samplesize>430</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>,Outside</recruitmentcountry>
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Professor Frank Bloomfield</primarysponsorname>
    <primarysponsoraddress>Liggins Institute / Department of Paediatrics
University of Auckland
Private Bag 92019
Auckland 1142</primarysponsoraddress>
    <primarysponsorcountry>New Zealand</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Nurture Foundation</fundingname>
      <fundingaddress>Level 12, ACH Support Building Auckland City Hospital 
PO Box 109-167
Newmarket
Auckland 1023</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Other</fundingtype>
      <fundingname>Gravida </fundingname>
      <fundingaddress>Liggins Institute
The University of Auckland
Building 505
85 Park Road
Grafton
Auckland 1023</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>Cure Kids </fundingname>
      <fundingaddress>Laundry Building
Suite 4, Level 4
58 Surrey Cresent
Grey Lynn 1021
Auckland </fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Lotteries Health Research</fundingname>
      <fundingaddress>The Department of Internal Affairs
46 Waring Taylor Street
WELLINGTON 6011
</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>A+ Trust </fundingname>
      <fundingaddress>Auckland District Health Board Charitable Trust
Private Bag 92024
Auckland 1023</fundingaddress>
      <fundingcountry>New Zealand</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Individual</sponsortype>
      <sponsorname>Professor Caroline Crowther</sponsorname>
      <sponsoraddress>Liggins Institute 
University of Auckland
Private Bag 92019
Auckland 1142</sponsoraddress>
      <sponsorcountry>New Zealand</sponsorcountry>
    </secondarysponsor>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Dr Cathryn Conlon</othercollaboratorname>
      <othercollaboratoraddress>Massey University
Institute of Food, Nutrition and Human Health
Private Bag 102 904
North Shore City 
Auckland 0745</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Professor Jane Harding </othercollaboratorname>
      <othercollaboratoraddress>Liggins Institute / Department of Paediatrics
University of Auckland
Private Bag 92019
Auckland 1142
New Zealand  
</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Individual</othercollaboratortype>
      <othercollaboratorname>Yannan Jiang </othercollaboratorname>
      <othercollaboratoraddress>Liggins Institute University of Auckland Private Bag 92019 Auckland 1142</othercollaboratoraddress>
      <othercollaboratorcountry>New Zealand</othercollaboratorcountry>
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>Postnatal growth restriction, or faltering growth, is almost universal in extremely low birthweight (ELBW) babies. This is largely due to inadequate nutrition, as it is very difficult to maintain nutritional intake in the smallest babies, particularly in the first week after birth. ELBW babies are also at risk of adverse neurodevelopmental outcomes, likely also due, in part, to inadequate nutrition. We have shown that increasing protein intakes in early life prevents faltering growth. We now propose to determine whether increased protein intake in early life in ELBW babies improves neurodevelopmental outcomes through a multicentre, double-blind randomised placebo-controlled trial. The findings of this trial will be of relevance to the management of all preterm babies because the intervention is simple and cheap. </summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Multiregion Ethics committee</ethicname>
      <ethicaddress>Ministry of Health
No 1 The Terrace
PO Box 5013
Wellington 6145</ethicaddress>
      <ethicapprovaldate>11/07/2013</ethicapprovaldate>
      <hrec>No  13/NTB/84</hrec>
      <ethicsubmitdate>14/06/2013</ethicsubmitdate>
      <ethiccountry>New Zealand</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>Ms</title>
      <name>Barbara Cormack</name>
      <address>Neonatal/Paediatric Dietitian
Nutrition Services 
Office 2, Level 8. Room 81.038 Support Building, Auckland City Hospital, Private Bag 920 24, Auckland 1142, New Zealand</address>
      <phone>Tel +64 9 307 4949 Ext 23351</phone>
      <fax />
      <email>bcormack@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Barbara Cormack</name>
      <address>Neonatal/Paediatric Dietitian
Nutrition Services 
Office 2, Level 8. Room 81.038 Support Building, Auckland City Hospital, Private Bag 920 24, Auckland 1142, New Zealand</address>
      <phone>Tel +64 9 307 4949 Ext 23351</phone>
      <fax />
      <email>bcormack@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Barbara Cormack</name>
      <address>Neonatal/Paediatric Dietitian
Nutrition Services 
Office 2, Level 8. Room 81.038 Support Building, Auckland City Hospital, Private Bag 920 24, Auckland 1142, New Zealand</address>
      <phone>Tel +64 9 307 4949 Ext 23351</phone>
      <fax />
      <email>bcormack@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>Ms</title>
      <name>Barbara Cormack</name>
      <address>Liggins Institute, University of Auckland, Grafton, Auckland    
or Neonatal/Paediatric Dietitian Nutrition Services Office 2, Level 8. Room 81.038 Support Building, Auckland City Hospital, Private Bag 920 24, Auckland 1142, New Zealand</address>
      <phone>Tel +64 9 307 4949 Ext 23351</phone>
      <fax />
      <email>bcormack@adhb.govt.nz</email>
      <country>New Zealand</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>